Mirtazapine is classified as a tetracyclic antidepressant, sometimes called an “atypical” tetracyclic. It also goes by a more specific pharmacological label: a noradrenergic and specific serotonergic antidepressant, or NaSSA. It’s the only NaSSA currently available in the United States, which makes it somewhat unique among antidepressants. Its only FDA-approved use is for major depressive disorder in adults, though it’s frequently prescribed off-label for insomnia and poor appetite.
What “Tetracyclic Antidepressant” Means
Antidepressants are grouped partly by their chemical structure and partly by how they work in the brain. Mirtazapine’s chemical structure has four connected rings of atoms, which is why it’s called a tetracyclic (tetra meaning four). This places it in a small, older family of medications that’s distinct from the more commonly prescribed SSRIs (like sertraline or fluoxetine) and SNRIs (like venlafaxine or duloxetine).
The tetracyclic label tells you about the molecule’s shape, but it doesn’t say much about what the drug actually does. That’s where the NaSSA classification becomes more useful.
How the NaSSA Class Works
The NaSSA label describes mirtazapine’s mechanism. Rather than blocking the reabsorption of brain chemicals the way SSRIs do, mirtazapine works by blocking specific receptors that normally act as “brakes” on two chemical messaging systems in the brain: norepinephrine and serotonin. Specifically, it blocks alpha-2 adrenergic receptors, which are essentially gatekeepers that tell the brain to stop releasing norepinephrine and serotonin. By turning off those brakes, mirtazapine allows both chemicals to flow more freely.
At the same time, mirtazapine blocks certain serotonin receptors (the 5-HT2 and 5-HT3 subtypes) while leaving others alone. This selective blocking is the “specific serotonergic” part of the NaSSA name, and it’s a big reason why mirtazapine’s side effect profile looks so different from SSRIs. Blocking 5-HT3 receptors, for instance, reduces nausea, which is why mirtazapine rarely causes the stomach upset that SSRIs are known for.
Mirtazapine also strongly blocks histamine receptors, the same receptors targeted by allergy medications like diphenhydramine. This is the main reason the drug causes drowsiness and increased appetite, two effects that are sometimes treated as side effects and sometimes as benefits, depending on the patient.
How It Compares to SSRIs
Because mirtazapine works through a completely different mechanism than SSRIs, the two classes produce noticeably different side effect patterns. A large review comparing mirtazapine head-to-head with SSRIs across multiple studies found clear trade-offs. Mirtazapine was about four times more likely to cause weight gain or increased appetite, and roughly twice as likely to cause drowsiness, fatigue, and dry mouth.
On the other hand, mirtazapine was far less likely to cause nausea (about one-third the risk), sexual dysfunction (also about one-third the risk), excessive sweating, headache, tremor, diarrhea, and sleep disturbance. For people who’ve struggled with the stomach problems or sexual side effects common with SSRIs, mirtazapine’s different class is often the reason a prescriber suggests switching.
Why Classification Affects Your Experience
Mirtazapine’s unique receptor profile creates a distinctive pattern that patients notice quickly. The histamine-blocking effect means most people feel noticeably sleepy within the first few doses, which is why it’s typically taken at bedtime. A large naturalistic study of nearly 5,000 patients found that mirtazapine’s effects on sleep and anxiety can appear within the first day or two, well before its antidepressant effects fully develop.
For depression itself, the timeline follows a recognizable curve. Improvement is fastest during the first two weeks, with patients improving roughly 2.6% per day during week one and 2.1% per day during week two. After that, progress continues but slows considerably, around 0.5% per day from weeks three through six. This early response pattern is part of why prescribers typically wait one to two weeks before considering a dose adjustment.
Typical Dosing
Mirtazapine is usually started at 15 mg once daily, taken in the evening before sleep. If the response isn’t adequate, the dose can be increased up to a maximum of 45 mg per day, with adjustments spaced at least one to two weeks apart. One counterintuitive feature of this drug: lower doses tend to be more sedating than higher doses, because at higher doses mirtazapine’s activating effects on norepinephrine start to offset the drowsiness from histamine blockade. So if sedation is a problem, increasing the dose sometimes helps rather than making it worse.
Where It Fits Among Antidepressants
In the broader landscape of antidepressants, mirtazapine occupies a niche. It’s not a first-line choice for most patients the way SSRIs are, but it fills specific gaps. Its appetite-stimulating and sleep-promoting properties make it particularly useful for people with depression accompanied by significant weight loss or insomnia. It’s also a common option for patients who can’t tolerate the sexual side effects or nausea that SSRIs produce. Its NaSSA classification, distinct from every other commonly prescribed antidepressant, is the reason it can serve these roles.